SELLAS Life Sciences Group (NASDAQ:SLS – Get Rating) and Kaya (OTCMKTS:KAYS – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.
Risk & Volatility
SELLAS Life Sciences Group has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Kaya has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.
This is a summary of current ratings and recommmendations for SELLAS Life Sciences Group and Kaya, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|SELLAS Life Sciences Group||0||0||2||0||3.00|
Earnings and Valuation
This table compares SELLAS Life Sciences Group and Kaya’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SELLAS Life Sciences Group||$7.60 million||6.25||-$20.70 million||($2.33)||-0.99|
|Kaya||$1.01 million||1.18||$7.80 million||N/A||N/A|
Kaya has lower revenue, but higher earnings than SELLAS Life Sciences Group.
This table compares SELLAS Life Sciences Group and Kaya’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|SELLAS Life Sciences Group||N/A||-221.83%||-131.81%|
Insider and Institutional Ownership
14.6% of SELLAS Life Sciences Group shares are held by institutional investors. 1.1% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
SELLAS Life Sciences Group beats Kaya on 9 of the 11 factors compared between the two stocks.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Kaya Holdings, Inc., a vertically integrated legal marijuana enterprise, produces, distributes, and/or sells a range of cannabis products in the United States. The company offers flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. It also operates two retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. The company also provides standing display cases with cannabis intended glassware under the Really Happy Glass brand; and t-shirt designs under the Kaya Gear brand name. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. was incorporated in 1993 and is headquartered in Fort Lauderdale, Florida.
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.